Sublingual treatment of food allergy
AssigneeStallergenes Greer International AG
InventorsGiampiero DE LUCA, Alessandro BERTI
Life of this patent
Estimating the term…
Abstract
The present invention provides therapies for use in treating a food allergy in a human patient, particular peanut protein allergy, comprising an accelerated up-dosing treatment protocol.
Claims14
A method of treating a peanut allergy in a human patient, wherein the treatment comprises sublingual administration of a food allergen in an up-dosing phase followed by a maintenance phase, wherein the up-dosing phase is of 24 to 28 days, and wherein the food allergen is peanut protein.
2-4. (canceled)
A method of treating a peanut allergy in a human patient, wherein the treatment comprises sublingual administration of a peanut protein, and the treatment comprises:
- a) an initial dose escalation phase that comprises administering sublingually to the patient a first dose of peanut protein of about 0.1 mg on day 1, and a second dose of allergen protein of about 0.3 mg on day 2;
- b) an up-dosing phase that comprises administering sublingually to the patient at least the following four different doses of peanut protein:
- i. a first dose phase comprising a first dose of about 0.5 mg administered daily for 7 days,
- ii. a second dose phase comprising a second dose of about 1.5 mg administered daily for 7 days,
- iii. a third dose phase comprising a third dose of about 2.5 mg administered daily for 7 days, and
- iv. a fourth dose phase comprising a fourth dose of about 4.0 mg administered daily for 7 days;
- and
- c) a maintenance phase that comprises administering sublingually to the patient a daily dose of peanut protein of about 4.0 mg for 52 weeks.
Dependencies are inferred from the claim text.